Kirby McInerney LLP is investigating potential claims against the Board of Directors of Furiex Pharmaceuticals, Inc. (“Furiex” or the “Company”) (NASDAQ:FURX) concerning the proposed acquisition of the Company by Forest Laboratories, Inc. (“Forest”) (NYSE:FRX). Under the terms of the definitive merger agreement, Furiex stockholders will receive $95 per share in cash and up to $30 per share in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex’s lead product, as a controlled drug following FDA approval.

The investigation concerns whether the Furiex Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the proposed consideration adequately values the Company’s common stock.

If you are a Furiex stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to

Copyright Business Wire 2010